US80105N1054 - ADR
SANOFI-ADR
NASDAQ:SNY (11/21/2024, 8:00:02 PM)
After market: 47.98 0 (0%)47.98
+0.2 (+0.42%)
Sanofi engages in the research, production, and distribution of pharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 87,994 full-time employees. The company went IPO on 2002-07-01. The firm focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
SANOFI-ADR
46 Avenue de la Grande Armee
Paris ILE-DE-FRANCE 75008
P: 33153774000
CEO: Paul Hudson
Employees: 86088
Website: https://www.sanofi.com/
SANOFI-ADR (NASDAQ:SNY) is probably undervalued for the fundamentals it is displaying.
One of these players has split its stock in the past. The other one hasn't.
No investor can ignore a crushing bottom-line beat and raised profitability guidance.
SNY earnings call for the period ending September 30, 2024.
Here you can normally see the latest stock twits on SNY, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: